Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus v… Read more
Vaxart Inc (VXRT) - Net Assets
Latest net assets as of September 2025: $26.76 Million USD
Based on the latest financial reports, Vaxart Inc (VXRT) has net assets worth $26.76 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($208.99 Million) and total liabilities ($182.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $26.76 Million |
| % of Total Assets | 12.8% |
| Annual Growth Rate | 8.23% |
| 5-Year Change | -52.25% |
| 10-Year Change | -15.22% |
| Growth Volatility | 142.14 |
Vaxart Inc - Net Assets Trend (1985–2024)
This chart illustrates how Vaxart Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vaxart Inc (1985–2024)
The table below shows the annual net assets of Vaxart Inc from 1985 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $58.92 Million | +1.94% |
| 2023-12-31 | $57.80 Million | -47.73% |
| 2022-12-31 | $110.60 Million | -41.02% |
| 2021-12-31 | $187.53 Million | +51.97% |
| 2020-12-31 | $123.40 Million | +852.78% |
| 2019-12-31 | $12.95 Million | +15.25% |
| 2018-12-31 | $11.24 Million | -39.90% |
| 2017-12-31 | $18.70 Million | -59.52% |
| 2016-12-31 | $46.20 Million | -33.53% |
| 2015-12-31 | $69.50 Million | -20.02% |
| 2014-12-31 | $86.90 Million | +27.79% |
| 2013-12-31 | $68.00 Million | -0.29% |
| 2012-12-31 | $68.20 Million | +15.85% |
| 2011-12-31 | $58.87 Million | -2.81% |
| 2010-12-31 | $60.57 Million | -37.82% |
| 2009-12-31 | $97.41 Million | -19.75% |
| 2008-12-31 | $121.38 Million | -17.16% |
| 2007-12-31 | $146.53 Million | +31.55% |
| 2006-12-31 | $111.39 Million | -31.17% |
| 2005-12-31 | $161.83 Million | -43.08% |
| 2004-12-31 | $284.32 Million | -10.96% |
| 2003-12-31 | $319.32 Million | +68.92% |
| 2002-12-31 | $189.03 Million | +0.97% |
| 2001-12-31 | $187.21 Million | +141.89% |
| 2000-12-31 | $77.39 Million | +32.98% |
| 1999-12-31 | $58.20 Million | +7.38% |
| 1998-12-31 | $54.20 Million | -28.40% |
| 1997-12-31 | $75.70 Million | -12.08% |
| 1996-12-31 | $86.10 Million | +24.06% |
| 1995-12-31 | $69.40 Million | +33.98% |
| 1994-12-31 | $51.80 Million | +187.78% |
| 1993-12-31 | $18.00 Million | +29.50% |
| 1992-12-31 | $13.90 Million | -7.95% |
| 1991-12-31 | $15.10 Million | +24.79% |
| 1990-12-31 | $12.10 Million | +24.74% |
| 1989-12-31 | $9.70 Million | +16.87% |
| 1988-12-31 | $8.30 Million | +3.75% |
| 1987-12-31 | $8.00 Million | +31.15% |
| 1986-12-31 | $6.10 Million | +125.93% |
| 1985-12-31 | $2.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vaxart Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46992200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $23.00K | 0.04% |
| Other Comprehensive Income | $4.00K | 0.01% |
| Other Components | $535.42 Million | 908.65% |
| Total Equity | $58.92 Million | 100.00% |
Vaxart Inc Competitors by Market Cap
The table below lists competitors of Vaxart Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Polyplex Corporation Limited
NSE:POLYPLEX
|
$135.91 Million |
|
ZUEBLIN IMMO.H.NAM.SF22,5
F:61Z1
|
$135.94 Million |
|
YTL Hospitality REIT
KLSE:5109
|
$135.98 Million |
|
Nippon Sharyo Ltd
MU:NIP
|
$135.99 Million |
|
Anhui Hyea Aromas Co Ltd
SHE:300886
|
$135.87 Million |
|
Dong Phu Rubber JSC
VN:DPR
|
$135.84 Million |
|
Avalue Technology
TWO:3479
|
$135.83 Million |
|
AnGes Inc
OTCGREY:AMGXF
|
$135.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vaxart Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 57,805,000 to 58,925,000, a change of 1,120,000 (1.9%).
- Net loss of 66,948,000 reduced equity.
- Share repurchases of 312,000 reduced equity.
- New share issuances of 56,292,000 increased equity.
- Other comprehensive income increased equity by 5,000.
- Other factors increased equity by 12,083,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-66.95 Million | -113.62% |
| Share Repurchases | $312.00K | -0.53% |
| Share Issuances | $56.29 Million | +95.53% |
| Other Comprehensive Income | $5.00K | +0.01% |
| Other Changes | $12.08 Million | +20.51% |
| Total Change | $- | 1.94% |
Book Value vs Market Value Analysis
This analysis compares Vaxart Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.62x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.35x to 5.62x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $1.96 | $0.68 | x |
| 1986-12-31 | $3.02 | $0.68 | x |
| 1987-12-31 | $3.17 | $0.68 | x |
| 1988-12-31 | $3.77 | $0.68 | x |
| 1989-12-31 | $4.80 | $0.68 | x |
| 1990-12-31 | $5.08 | $0.68 | x |
| 1991-12-31 | $6.34 | $0.68 | x |
| 1992-12-31 | $6.12 | $0.68 | x |
| 1993-12-31 | $8.64 | $0.68 | x |
| 1994-12-31 | $19.44 | $0.68 | x |
| 1995-12-31 | $13.64 | $0.68 | x |
| 1996-12-31 | $15.81 | $0.68 | x |
| 1997-12-31 | $14.27 | $0.68 | x |
| 1998-12-31 | $10.25 | $0.68 | x |
| 1999-12-31 | $10.72 | $0.68 | x |
| 2000-12-31 | $13.54 | $0.68 | x |
| 2001-12-31 | $27.54 | $0.68 | x |
| 2002-12-31 | $31.50 | $0.68 | x |
| 2003-12-31 | $43.19 | $0.68 | x |
| 2004-12-31 | $32.01 | $0.68 | x |
| 2005-12-31 | $17.84 | $0.68 | x |
| 2006-12-31 | $12.06 | $0.68 | x |
| 2007-12-31 | $16.04 | $0.68 | x |
| 2008-12-31 | $15.45 | $0.68 | x |
| 2009-12-31 | $12.70 | $0.68 | x |
| 2010-12-31 | $9.00 | $0.68 | x |
| 2011-12-31 | $9.18 | $0.68 | x |
| 2012-12-31 | $26.59 | $0.68 | x |
| 2013-12-31 | $2.65 | $0.68 | x |
| 2014-12-31 | $3.05 | $0.68 | x |
| 2015-12-31 | $2.16 | $0.68 | x |
| 2016-12-31 | $1.32 | $0.68 | x |
| 2017-12-31 | $5.32 | $0.68 | x |
| 2018-12-31 | $0.18 | $0.68 | x |
| 2019-12-31 | $0.06 | $0.68 | x |
| 2020-12-31 | $0.25 | $0.68 | x |
| 2021-12-31 | $0.38 | $0.68 | x |
| 2022-12-31 | $0.23 | $0.68 | x |
| 2023-12-31 | $0.12 | $0.68 | x |
| 2024-12-31 | $0.12 | $0.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vaxart Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -113.62%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -233.27%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 2.82x
- Recent ROE (-113.62%) is below the historical average (-23.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 37.04% | 2.92% | 3.42x | 3.70x | $730.00K |
| 1986 | 13.11% | 1.83% | 3.26x | 2.20x | $190.00K |
| 1987 | 6.25% | 1.16% | 3.17x | 1.70x | $-300.00K |
| 1988 | 2.41% | 0.42% | 2.26x | 2.52x | $-630.00K |
| 1989 | 8.25% | 1.35% | 2.43x | 2.52x | $-170.00K |
| 1990 | 18.18% | 3.02% | 3.07x | 1.96x | $990.00K |
| 1991 | 14.57% | 3.23% | 2.56x | 1.76x | $690.00K |
| 1992 | -4.32% | -0.73% | 1.73x | 3.42x | $-1.99 Million |
| 1993 | 19.44% | 3.44% | 1.92x | 2.94x | $1.70 Million |
| 1994 | 15.25% | 4.80% | 1.76x | 1.81x | $2.72 Million |
| 1995 | -25.36% | -8.71% | 1.46x | 1.99x | $-24.54 Million |
| 1996 | 15.45% | 5.54% | 1.19x | 2.35x | $4.69 Million |
| 1997 | -14.80% | -4.90% | 1.01x | 2.98x | $-18.77 Million |
| 1998 | -40.22% | -8.97% | 1.11x | 4.03x | $-27.22 Million |
| 1999 | 5.67% | 1.41% | 1.09x | 3.69x | $-2.52 Million |
| 2000 | 5.63% | 1.91% | 1.02x | 2.90x | $-3.38 Million |
| 2001 | 55.92% | 44.58% | 0.76x | 1.66x | $85.96 Million |
| 2002 | 1.09% | 1.05% | 0.84x | 1.23x | $-16.85 Million |
| 2003 | -2.14% | -3.87% | 0.46x | 1.21x | $-38.76 Million |
| 2004 | -17.72% | -35.44% | 0.39x | 1.29x | $-78.82 Million |
| 2005 | -79.37% | -118.87% | 0.33x | 2.04x | $-144.63 Million |
| 2006 | -52.70% | -65.32% | 0.34x | 2.39x | $-69.84 Million |
| 2007 | 32.12% | 0.00% | 0.00x | 1.63x | $32.42 Million |
| 2008 | -15.44% | 0.00% | 0.00x | 1.19x | $-30.88 Million |
| 2009 | -19.23% | -178.54% | 0.08x | 1.35x | $-28.47 Million |
| 2010 | 1.45% | 2.51% | 0.31x | 1.88x | $-5.18 Million |
| 2011 | -7.70% | -30.54% | 0.15x | 1.66x | $-10.42 Million |
| 2012 | -12.76% | -25.89% | 0.40x | 1.24x | $-15.52 Million |
| 2013 | -13.09% | -26.49% | 0.39x | 1.26x | $-15.70 Million |
| 2014 | -12.66% | -16.01% | 0.60x | 1.31x | $-19.69 Million |
| 2015 | -27.48% | -77.64% | 0.31x | 1.14x | $-26.05 Million |
| 2016 | -54.98% | -273.12% | 0.13x | 1.57x | $-30.02 Million |
| 2017 | -66.63% | -213.39% | 0.15x | 2.14x | $-14.33 Million |
| 2018 | -160.23% | -432.96% | 0.12x | 3.13x | $-19.13 Million |
| 2019 | -143.95% | -189.06% | 0.27x | 2.86x | $-19.94 Million |
| 2020 | -26.11% | -796.34% | 0.03x | 1.24x | $-44.56 Million |
| 2021 | -37.58% | -7900.22% | 0.00x | 1.18x | $-89.22 Million |
| 2022 | -97.43% | -100708.41% | 0.00x | 1.39x | $-118.82 Million |
| 2023 | -142.66% | -1117.56% | 0.08x | 1.59x | $-88.25 Million |
| 2024 | -113.62% | -233.27% | 0.17x | 2.82x | $-72.84 Million |
Industry Comparison
This section compares Vaxart Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vaxart Inc (VXRT) | $26.76 Million | 37.04% | 6.81x | $135.87 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |